Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Interferon gamma-1b
Drug ID BADD_D01171
Description Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Indications and Usage Interferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB00033
KEGG ID D00747
MeSH ID C554125
PubChem ID Not Available
TTD Drug ID D0U9EN
NDC Product Code 17089-378; 75987-111
UNII 21K6M2I7AG
Synonyms interferon gamma-1b | interferon gamma-2a | Actimmune
Chemical Information
Molecular Formula Not Available
CAS Registry Number 98059-61-1
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alanine aminotransferase increased13.03.04.005--
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Atrioventricular block02.03.01.002--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Cardiac failure02.05.01.001--
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.009--Not Available
Chills15.05.03.016; 08.01.09.001--
Clubbing22.12.02.004; 02.11.04.003; 15.03.02.006--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Death08.04.01.001--
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Dermatomyositis10.04.04.027; 23.03.02.001; 15.05.01.002--Not Available
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dyspepsia07.01.02.001--
Fatigue08.01.01.002--
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.016--
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatomegaly09.01.05.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypertriglyceridaemia14.08.02.001--
Hyponatraemia14.05.04.002--
Hypotension24.06.03.002--
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene